DOI 10.1016/j.anai.2019.11.018
Future therapies for eosinophilic gastrointestinal disorders.
Аннотация
OBJECTIVE
To review novel therapeutics in development for treatment of eosinophilic gastrointestinal disorders (EGIDs).
DATA SOURCES: Clinical trial data (clinicaltrials.gov) and literature search on PubMed.
STUDY SELECTIONS: Studies on treatment and clinical trials in EGIDs were included in this review.
RESULTS
During the past decade, significant progress has been made in understanding disease mechanisms in EGIDs. As a result, a variety of novel therapeutics have been developed for treatment of these disorders. Several monoclonal antibodies against targets, including interleukin (IL) 4, IL-5, IL-13, integrins, and siglec-8, have shown promise in early trials. Novel formulations of corticosteroids are also in development.
CONCLUSION
The field of EGID research has advanced rapidly, and disease-modifying therapeutics are closer to clinical application.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.